Cardiovascular Risk in Testicular Cancer Survivors Treated With Chemotherapy: Incidence, Significance, and Practice Implications

Barbara H. Zoltick

Linda A. Jacobs

David J. Vaughn

ONF 2005, 32(5), 1005-1012. DOI: 10.1188/05.ONF.1005-1012

Purpose/Objectives: To explore what is known regarding cardiovascular late effects of treatment, such as Raynaud phenomenon, hypertension, hyperlipidemia, and coronary artery disease as well as the risk for cardiovascular events experienced by patients with testicular cancer treated with chemotherapy.

Jump to a section

    References

    Berger, C.C., Bokemeyer, C., Schneider, M., Kuczyk, M.A., & Schmoll, H.J. (1995). Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. European Journal of Cancer, 31A, 2229-2238.

    Bokemeyer, C., Berger, C.C., Kuczyk, M.A., & Schmoll, H.J. (1996). Evaluation of long-term toxicity after chemotherapy for testicular cancer. Journal of Clinical Oncology, 14, 2923-2932.

    Bosl, G.J., Leitner, S.P., Atlas, S.A., Sealey, J.E., Preibisz, J.J., & Scheiner, E. (1986). Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. Journal of Clinical Oncology, 4, 1684-1689.

    Boyer, M., Raghavan, D., Harris, P.J., Lietch, J., Bleasel, A., Walsh, J.C., et al. (1990). Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. Journal of Clinical Oncology, 8, 21-26.

    Chaudhary, U.B., & Haldas, J.R. (2003). Long-term complications of chemotherapy for germ cell tumours. Drugs, 63, 1565-1577.

    Dodd, P.M., & Kelly, W.K. (2001). Testicular cancer. In R.E. Lenhard, Jr., R.T. Osteen, & T. Gansler (Eds.), Clinical oncology (1st ed., 419-426). Atlanta, GA: American Cancer Society.

    Einhorn, L.H. (1981). Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Research, 41(9, Pt. 1), 3275-3280.

    Gerl, A. (1994). Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs, 5, 607-614.

    Hennessy, B., O'Connor, M., & Carney, D.N. (2002). Acute vascular events associated with cisplatin therapy in malignant disease. Irish Medical Journal, 95(5), 145-146, 148.

    Huddart, R.A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., et al. (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. Journal of Clinical Oncology, 21, 1513-1523.

    Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., et al. (2005). Cancer statistics, 2005. CA: A Cancer Journal for Clinicians, 55, 10-30.

    Meinardi, M.T., Gietema, J.A., van der Graaf, W.T., van Veldhuisen, D.J., Runne, M.A., Sluiter, W.J., et al. (2000). Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. Journal of Clinical Oncology, 18, 1725-1732.

    Meinardi, M.T., Gietema, J.A., van Veldhuisen, D.J., van der Graaf, W.T., de Vries, E.G., & Sleijfer, D.T. (2000). Long-term chemotherapy-related cardiovascular morbidity. Cancer Treatment Reviews, 26, 429-447.

    National Comprehensive Cancer Network. (2004). Clinical prectice guidelines in oncology: Testicular cancer [Version 1.2004]. Jenkintown, PA: Author.

    Nord, C., Fossa, S.D., & Egeland, T. (2003). Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. British Journal of Cancer, 88, 36-41.

    Raghavan, D., Cox, K., Childs, A., Grygiel, J., & Sullivan, D. (1992). Hyper-cholesterolemia after chemotherapy for testis cancer. Journal of Clinical Oncology, 10, 1386-1389.

    Strumberg, D., Brugge, S., Korn, M.W., Koeppen, S., Ranft, J., Scheiber, G., et al. (2002). Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Annals of Oncology, 13, 229-236.

    Vaughn, D.J., Gignac, G.A., & Meadows, A.T. (2002). Long-term medical care of testicular cancer survivors. Annals of Internal Medicine, 136, 463-470.

    Vogelzang, N.J., Torkelson, J.L., & Kennedy, B.J. (1985). Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer, 56, 2765-2770.